Education
About Us
Working with TipRanks
Follow Us
bioAffinity Technologies, Inc. (BIAF)
NASDAQ:BIAF
BIAF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.26 - $3.16
Previous CloseN/A
Volume17.91K
Average Volume (3M)115.97K
Market Cap
N/A
Enterprise Value$26.74M
Total Cash (Recent Filing)$83.11K
Total Debt (Recent Filing)$10.01M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Mar 28, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding15,584,635
10 Day Avg. Volume222,236
30 Day Avg. Volume115,971
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.62
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit33.78
Enterprise Value/Ebitda-3.46
Forecast
1Y Price Target
$6.00Price Target Upside1521.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
bioAffinity Technologies, Inc. News
PremiumCompany Announcements
bioAffinity Technologies Adjusts CEO Compensation Package
PremiumCompany Announcements
bioAffinity Technologies Boosts Sales with CyPath Lung
PremiumCompany Announcements
bioAffinity Technologies Reports Strong Q3 Growth
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe number of physician offices ordering CyPath Lung was roughly 140, up from ~100 at the end of 2Q24, indicating growth potential.
Product DevelopmentBIAF is focused on changing the paradigm for the early detection of cancers, and its initial product, CyPath Lung, could become the standard-of-care.
Bears Say
Financial PerformanceBIAF reported 3Q24 results with revenue slightly below our estimate and a slightly wider GAAP loss per share.
---
Ownership Overview
28.25% Insiders
2.20% Mutual Funds
0.31% Other Institutional Investors
67.57% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BIAF FAQ
What was bioAffinity Technologies, Inc.’s price range in the past 12 months?
bioAffinity Technologies, Inc. lowest stock price was $0.26 and its highest was $3.16 in the past 12 months.
What is bioAffinity Technologies, Inc.’s market cap?
Currently, no data Available
When is bioAffinity Technologies, Inc.’s upcoming earnings report date?
bioAffinity Technologies, Inc.’s upcoming earnings report date is Mar 28, 2025 which is in 17 days.
How were bioAffinity Technologies, Inc.’s earnings last quarter?
bioAffinity Technologies, Inc. released its earnings results on Nov 14, 2024. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.01.
Is bioAffinity Technologies, Inc. overvalued?
According to Wall Street analysts bioAffinity Technologies, Inc.’s price is currently Undervalued.
Does bioAffinity Technologies, Inc. pay dividends?
bioAffinity Technologies, Inc. does not currently pay dividends.
What is bioAffinity Technologies, Inc.’s EPS estimate?
bioAffinity Technologies, Inc.’s EPS estimate is -0.14.
How many shares outstanding does bioAffinity Technologies, Inc. have?
bioAffinity Technologies, Inc. has 15,584,635 shares outstanding.
What happened to bioAffinity Technologies, Inc.’s price movement after its last earnings report?
bioAffinity Technologies, Inc. reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went up 3.101%.
Which hedge fund is a major shareholder of bioAffinity Technologies, Inc.?
Currently, no hedge funds are holding shares in BIAF
---
Company Description
bioAffinity Technologies, Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.
---
BIAF Stock 12 Month Forecast
Average Price Target
$6.00
▲(1521.62% Upside)
Technical Analysis
Best Analysts Covering BIAF
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-79.17%
reiterated a buy rating 4 months ago
Copying Anthony Vendetti's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -79.17% per trade.
---